Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

36.57 +0.58 (+1.61%)
Official Closing Price Updated: 7:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,547,381
Open 36.03
Bid (Size) 33.66 (1)
Ask (Size) 37.80 (1)
Prev. Close 35.99
Today's Range 35.98 - 36.59
52wk Range 33.20 - 39.74
Shares Outstanding 5,385,189,617
Dividend Yield 3.95%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These biotechs targeting multiple neurodegenerative diseases
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market. 
Via MarketBeat
Competition and Optimism: GSK's CEO Walmsley Foresees Growth Despite Competition In RSV Vaccine Market
Emma Walmsley, the Chief Executive Officer of GSK plc (NYSE: GSK), expressed confidence in its respiratory syncytial virus (RSV) vaccine, Arexvy, anticipating sales to surpass £1 billio 
Via Benzinga

Performance

YTD
+3.63%
+3.63%
1 Month
+5.75%
+5.75%
3 Month
+4.40%
+4.40%
6 Month
+7.21%
+7.21%
1 Year
+4.40%
+4.40%

More News

Read More
3 Stocks to Sell for Tax Losses Before the New Year
Via InvestorPlace
3 Great Foreign Companies to Invest in Right Now
Via The Motley Fool
GSK Frames A Comeback For Its Multiple Myeloma Drug Following Encouraging Phase 3 Data
Via Benzinga
Price Over Earnings Overview: GSK
Via Benzinga
Looking Into GSK's Recent Short Interest
Via Benzinga
Merck's Latest Drug For Chronic Cough Faces FDA Pushback
Via Benzinga
Exposures Product Safety
Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion
Via Benzinga
Diversifying Your Portfolio With Plant-Based Options
Via Talk Markets
Major Buyout Firms Eye Sanofi's Consumer Health Division Spinoff Valued Over $20B
Via Benzinga
Current Analysis: GSK Plc
Via Talk Markets
Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
European Drug Regulator Recommends Approval Of GSK's Bone Marrow Cancer Med
Via Benzinga
GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative
From GSK plc
Via Business Wire
6 Nasdaq 100 Stocks Down 40% or More that Will Soar As Much 367%
Via InvestorPlace
GSK is a remedy for the winter investment blahs
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
3 Healthcare Stocks Getting Help From the Aging Population
Via InvestorPlace
3 Top Dividend Stock Picks for Steady Income and Capital Appreciation
Via InvestorPlace
Moderna Beats Sales Forecasts, But Light Guidance Could Rattle Shares
Via Investor's Business Daily
GSK Hikes Guidance On The Back Of Its Strong RSV Vaccine Launch
Via Investor's Business Daily
GSK Lifts Annual Guidance Again Helped By Strong Launch Of RSV Vaccine, Steady Demand For Shingles Shot
Via Benzinga
Nasdaq, S&P 500 Futures Slide Ahead Of Fed Decision, Economic Data: Analyst Tells Why November Could Herald 'Good News'
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Johnson & Johnson Offloads Rights For Hepatitis B Candidate To GSK
Via Benzinga
Earnings Scheduled For November 1, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.